A Revolutionary Approach to Diabetes Management
Millions of people worldwide rely on daily insulin injections to manage their diabetes. Avant Technologies and SGAustria are partnering to change that. Their innovative approach uses cell encapsulation technology to offer a potential long-term solution.
This partnership combines Avant’s work in developing cell-based therapies with SGAustria’s clinically proven Cell-in-a-Box® technology. The collaboration will operate under a new U.S. company, Insulinova, Inc., which will conduct clinical trials.
The Challenge of Diabetes
The International Diabetes Federation reports that 1 in 9 adults has diabetes, and many are unaware of their condition. By 2050, the number of people with diabetes is expected to reach 853 million. Traditional treatments help manage symptoms but do not address the root cause.
| Diabetes Statistics | Key Figures |
|---|---|
| Adults with Diabetes | 1 in 9 (20-79 years) |
| Unaware of Condition | 4 in 10 |
| Global Cases (Current) | 589 million |
| Projected Global Cases (2050) | 853 million |
How Cell Encapsulation Works
Cell encapsulation technology protects genetically modified cells that produce insulin. These cells are placed in a protective barrier, shielding them from the body’s immune system. This allows the cells to function like healthy pancreatic beta cells, releasing insulin as needed.
“Our Cell-in-a-Box® technology is a pivotal advancement for a diabetes treatment, and through our joint venture with Avant, we are poised to deliver a transformative therapy,” said Brian Salmons, CEO at SGAustria.
This technology eliminates the need for immunosuppressive drugs, which carry significant risks. It also prevents complications like cell escape or tumor formation, making it a safe and scalable solution.
A Future Without Daily Injections
This new therapy has shown promising results in preclinical and clinical studies. Encapsulated cells have been shown to control glucose levels in patients, improving their overall well-being.
“By partnering with SGAustria, we’re ensuring that any genetically modified insulin-producing cells that we develop together can thrive in the body long-term and offer the potential of restoring natural glucose control and dramatically improving patients’ quality of life,” said Chris Winter, CEO at Avant.
This partnership between Avant Technologies and SGAustria marks a significant step forward in the search for a long-term solution for diabetes. It offers hope for a future where managing diabetes is no longer a daily burden.
References
[1] Avant Technologies, Inc. (2025, December 16). Avant Technologies Highlights the Critical Role of Cell Encapsulation Technology in Revolutionizing Diabetes Treatment. PR Newswire. Retrieved from https://www.prnewswire.com/news-releases/avant-technologies-highlights-the-critical-role-of-cell-encapsulation-technology-in-revolutionizing-diabetes-treatment-302642802.html
